Program
Adalimumab
Also written as “adalimumab”, “MSB11022” and “M923”.
Its studies are mostly in Arthritis, Rheumatoid · Psoriasis · Crohn Disease · Colitis, Ulcerative · Hidradenitis Suppurativa, led by 17 companies.
Drug pageAdalimumab: every studyMany companies study it; this page follows only the 149 they lead. All 319 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Abbottits history only | 620 open or running | phase 4since Sep 13, 2005 | Nov 1, 2002 | none ahead |
| AbbVieits history only | 543 open or running | phase 4since May 25, 2010 | Sep 13, 2005 | Sep 2027phase 2 · NCT06257875 |
| Alvotech Swissits history only | 60 open or running | phase 3since Feb 5, 2019 | Jun 8, 2018 | none ahead |
| Johnson & Johnsonits history only | 50 open or running | phase 3since Dec 18, 2013 | Dec 18, 2013 | none ahead |
| Fresenius Kabiits history only | 40 open or running | phase 3since Jan 17, 2016 | Jan 17, 2016 | none ahead |
| Biocadits history only | 30 open or running | phase 3since Mar 31, 2016 | Mar 16, 2015 | none ahead |
| Cinnagenits history only | 20 open or running | phase 3since May 24, 2017 | May 24, 2017 | none ahead |
| Sino Biopharmaceuticalits history only | 22 open or running | phase 4since Apr 8, 2026 | Apr 8, 2026 | Apr 2028phase 4 · NCT07529925 |
| Takedaits history only | 20 open or running | phase 4since May 5, 2016 | Mar 15, 2015 | none ahead |
| Viatrisits history only | 20 open or running | phase 3since Nov 9, 2015 | Jun 3, 2015 | none ahead |
| care-arthritis-ltdits history only | 10 open or running | phase 2since Feb 24, 2015 | Feb 24, 2015 | none ahead |
| Celltrionits history only | 10 open or running | phase 3since Sep 18, 2019 | Sep 18, 2019 | none ahead |
| LG Chemits history only | 10 open or running | phase 1since Jul 30, 2014 | Jul 30, 2014 | none ahead |
| mabscale-llcits history only | 11 open or running | phase 3since Jul 5, 2023 | Jul 5, 2023 | none ahead |
| National Resilienceits history only | 10 open or running | phase 3since Jan 10, 2021 | Jan 10, 2021 | none ahead |
| prestige-biopharma-limitedits history only | 11 open or running | phase 1since Oct 1, 2021 | Oct 1, 2021 | Jun 2027phase 1 · NCT05108259 |
| Samsung Bioepisits history only | 10 open or running | phase 1since Aug 13, 2020 | Aug 13, 2020 | none ahead |
Also a collaborator on its studies: Merck KGaA, Darmstadt, Germany, Mylan, Pharm-Olam, PPD DEVELOPMENT, LP, PRA Health Sciences, IST GmbH, Germany, Parexel, Pivotal S.L., GlaxoSmithKline, Regeneron Pharmaceuticals, Eisai and Abbott Japan.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 45 earlier studies, Jun 14, 2012 to Jul 11, 2019.
- Dec 9, 2017Named adalimumabINNProposed as its International Nonproprietary Name in WHO's List 118 · before, MSB11022, M923
- Sep 18, 2019Celltrion’s first study: phase 3 study in Arthritis, RheumatoidNew to CelltrionCelltrion · NCT04171414 · 62 enrolled · Poland
- Dec 10, 2019Phase 3 study in RAAlvotech Swiss · NCT04224194 · 107 enrolled · Georgia, Ukraine
- May 15, 2020Phase 3 study in Plaque PsoriasisAlvotech Swiss · NCT04453137 · 567 enrolled · Georgia, Iceland, Poland and more
- Aug 13, 2020Samsung Bioepis’s first study: phase 1 study in HealthyNew to Samsung BioepisSamsung Bioepis · NCT04514796 · 188 enrolled · Germany
- Jan 10, 2021National Resilience’s first study: phase 3 study in Mild to Moderate COVID-19New to National ResilienceNational Resilience · NCT04705844
- Oct 1, 2021prestige-biopharma-limited’s first study: phase 1 study in Healthy VolunteersNew to prestige-biopharma-limitedprestige-biopharma-limited · NCT05108259 · 160 enrolled · Spain
- Jun 8, 2022Phase 4 study in Non-infectious Intermediate Posterior- or Pan-uveitisAbbVie · NCT05414201 · 87 enrolled · China
- Apr 4, 2023Phase 3 study in Arthritis, RheumatoidAbbVie · NCT05814627 · 487 enrolled · United States, Argentina, Belgium and more
- May 22, 2023Phase 1 study in HealthyJohnson & Johnson · NCT05884242 · 20 enrolled · Belgium
- Jul 5, 2023mabscale-llc’s first study: phase 3 study in Plaque PsoriasisNew to mabscale-llcmabscale-llc · NCT06005532 · 494 planned · Russian Federation
- Oct 2, 2023Phase 2 study in Colitis, UlcerativeAbbVie · NCT06257875 · 156 enrolled · United States, Australia, Austria and more
- Oct 20, 2023Phase 3 study in Arthritis, JuvenileAbbVie · NCT06100744 · 40 planned · United States, Australia, Canada and more
- Sep 12, 2025Phase 1 study in Healthy Adult MaleBiocad · NCT07181694 · 444 enrolled · Russia
- Apr 8, 2026Sino Biopharmaceutical’s first studies: 2 phase 4 studiesNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT07529925, NCT07564505
Ahead
- Jun 2027Primary completion: phase 1 study in Healthy Volunteersprestige-biopharma-limited · NCT05108259
- Sep 2027Primary completion: phase 2 study in Colitis, UlcerativeAbbVie · NCT06257875
- Apr 2028Primary completion: phase 4 study in Severe Plaque Psoriasis in Chinese ChildrenSino Biopharmaceutical · NCT07529925
- Mar 2029Primary completion: phase 4 study in Children Aged 6 Years and Above With Moderate - to - Severe Active Crohn's DiseaseSino Biopharmaceutical · NCT07564505
TargetBeta
“TNF-alpha inhibitor”ChEMBL 37, by rule
Other programs on TNF
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Brentuximab Vedotinrule | Pfizer | phase 4 | 37 |
| CHS-1420rule | nanjing-king-friend-biochemical-pharmaceutical-co-ltd | phase 3 | 2 |
| brivekimig | Sanofi | phase 2 | 6 |
| Hadlimarule | biora-therapeutics-inc | phase 1 | 1 |
Studies
The newest 60 of 149 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07564505Children Aged 6 Years and Above With Moderate - to - Severe Active Crohn's Disease · China | 4 | Recruiting | Sino Biopharmaceutical | Mar 2029 | 30 |
| NCT07529925Severe Plaque Psoriasis in Chinese Children | 4 | Not yet recruiting | Sino Biopharmaceutical | Apr 2028 | 30 |
| NCT07181694Healthy Adult Male · Russia | 1 | Completed | Biocad | Feb 12, 2026 | 444 |
| NCT06100744Arthritis, Juvenile · United States, Australia, Canada and more | 3 | Recruiting | AbbVie | Sep 2026 | 40 |
| NCT06257875Colitis, Ulcerative · United States, Australia, Austria and more | 2 | Active, not recruiting | AbbVie | Sep 2027 | 156 |
| NCT06005532Plaque Psoriasis · Russian Federation | 3 | Recruiting | mabscale-llc | Mar 2025 | 494 |
| NCT05884242Healthy · Belgium | 1 | Completed | Johnson & Johnson | Aug 1, 2023 | 20 |
| NCT05814627Arthritis, Rheumatoid · United States, Argentina, Belgium and more | 3 | Completed | AbbVie | Jul 15, 2026 | 487 |
| NCT05414201Non-infectious Intermediate Posterior- or Pan-uveitis · China | 4 | Completed | AbbVie | Jun 10, 2024 | 87 |
| NCT05108259Healthy Volunteers · Spain | 1 | Active, not recruiting | prestige-biopharma-limited | Jun 2027 | 160 |
| NCT04705844Mild to Moderate COVID-19 | 3 | Withdrawn | National Resilience | Sep 2022 | 0 |
| NCT04514796Healthy · Germany | 1 | Completed | Samsung Bioepis | May 15, 2021 | 188 |
| NCT04453137Plaque Psoriasis · Georgia, Iceland, Poland and more | 3 | Completed | Alvotech Swiss | May 31, 2021 | 567 |
| NCT04224194RA · Georgia, Ukraine | 3 | Completed | Alvotech Swiss | Jul 8, 2020 | 107 |
| NCT04171414Arthritis, Rheumatoid · Poland | 3 | Completed | Celltrion | Nov 4, 2019 | 62 |
| NCT04018599Arthritis, Rheumatoid · United States | 1 | Completed | Fresenius Kabi | Mar 17, 2020 | 216 |
| NCT03983876Phase 1 · New Zealand | 1 | Completed | Alvotech Swiss | Dec 3, 2019 | 207 |
| NCT03849404Plaque Psoriasis · Estonia, Georgia, Poland and more | 3 | Completed | Alvotech Swiss | Dec 23, 2019 | 413 |
| NCT03849313Healthy Volunteers · Australia, New Zealand | 1 | Completed | Alvotech Swiss | Feb 17, 2020 | 390 |
| NCT03823391Arthritis, Rheumatoid · United States, Germany, Hungary and more | 2 | Completed | AbbVie | Apr 8, 2020 | 48 |
| NCT03579823Healthy Volunteers · Australia | 1 | Completed | Alvotech Swiss | Aug 24, 2018 | 24 |
| NCT03311464Pyoderma Gangrenosum · Japan | 3 | Completed | AbbVie | Aug 20, 2019 | 22 |
| NCT03273192Bioequivalence · Iran, Islamic Republic of | 1 | Completed | Cinnagen | Aug 6, 2017 | 74 |
| NCT03172325Active Rheumatoid Arthritis · Iran, Islamic Republic of | 3 | Completed | Cinnagen | Aug 17, 2016 | 136 |
| NCT03052322Moderate to Severe Rheumatoid Arthritis · Bulgaria, Czechia, Germany and more | 3 | Completed | Fresenius Kabi | May 28, 2018 | 288 |
| NCT03014947Healthy Subjects | 1 | Completed | Fresenius Kabi | Dec 2014 | 237 |
| NCT02904902Hidradenitis Suppurativa · Japan | 3 | Completed | AbbVie | Sep 1, 2017 | 15 |
| NCT02897115Axial Spondyloarthritis | 4 | Terminated | AbbVie | Dec 21, 2017 | 22 |
| NCT02814175Arthritis, Psoriatic · United States, Australia, Brazil and more | 4 | Completed | AbbVie | Sep 23, 2019 | 246 |
| NCT02808975Hidradenitis Suppurativa · United States, Belgium, Canada and more | 4 | Completed | AbbVie | May 16, 2019 | 206 |
| NCT02764762Crohn Disease · United States, Canada | 4 | Completed | Takeda | Sep 22, 2020 | 55 |
| NCT02762955Psoriasis · Russian Federation | 3 | Completed | Biocad | Dec 2017 | 344 |
| NCT02722044Arthritis, Rheumatoid · United States | 3 | Completed | Johnson & Johnson | Feb 21, 2017 | 33 |
| NCT02675023Healthy · United States, United Kingdom | 1 | Completed | Johnson & Johnson | Jul 2016 | 603 |
| NCT02660580Psoriasis · United States, Bulgaria, Canada and more | 3 | Completed | Fresenius Kabi | Dec 31, 2016 | 443 |
| NCT02632175Colitis, Ulcerative · United States, Japan, Poland and more | 3 | Completed | AbbVie | Apr 8, 2025 | 59 |
| NCT02629159Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Active, not recruiting | AbbVie | Oct 27, 2017 | 1,629 |
| NCT02714322Psoriasis · Bulgaria, Estonia, Hungary and more | 3 | Completed | Viatris | May 2016 | 294 |
| NCT02581345Psoriasis · United States, Bulgaria, Canada and more | 3 | Completed | Johnson & Johnson | Apr 4, 2017 | 572 |
| NCT02533375Psoriasis | 3 | Completed | AbbVie | Sep 15, 2016 | 10 |
| NCT02499783Crohn Disease | 3 | Completed | AbbVie | May 19, 2017 | 205 |
| NCT02472912Healthy Volunteers · Belgium | 1 | Completed | Viatris | May 2015 | 270 |
| NCT02395055Healthy · Russian Federation | 1 | Completed | Biocad | Oct 2015 | 94 |
| NCT02393378Arthritis, Rheumatoid · Czechia, Estonia, Russian Federation and more | 2 | Terminated | Takeda | Jun 27, 2016 | 7 |
| NCT02471118Osteoarthritis, Knee · Canada | 2 | Completed | care-arthritis-ltd | Mar 2021 | 62 |
| NCT02206867Healthy Subjects | 1 | Completed | LG Chem | Feb 2015 | 116 |
| NCT02198651Arthritis, Rheumatoid · United States, Australia, Austria and more | 4 | Completed | AbbVie | May 3, 2018 | 149 |
| NCT02196701Psoriasis | 3 | Completed | AbbVie | Mar 17, 2017 | 46 |
| NCT02185014Crohn Disease | 3 | Completed | AbbVie | Nov 3, 2017 | 252 |
| NCT02148718Crohn Disease | 4 | Completed | AbbVie | Aug 2016 | 100 |
| NCT02065622Colitis, Ulcerative · United States, Austria, Belgium and more | 3 | Completed | AbbVie | Sep 5, 2019 | 952 |
| NCT02065570Crohn Disease · United States, Austria, Belgium and more | 3 | Completed | AbbVie | Jan 30, 2020 | 514 |
| NCT02065557Colitis, Ulcerative · United States, Australia, Austria and more | 3 | Completed | AbbVie | Feb 7, 2020 | 101 |
| NCT02019472Arthritis, Rheumatoid · United States, Bulgaria, Chile and more | 3 | Completed | Johnson & Johnson | Aug 17, 2016 | 559 |
| NCT02016482Nail Psoriasis | 3 | Completed | AbbVie | Oct 2015 | 217 |
| NCT02015793Crohn Disease | 2 | Completed | AbbVie | Feb 2015 | 30 |
| NCT01958827Crohn Disease | 3 | Completed | AbbVie | Mar 2015 | 28 |
| NCT01808118Axial Spondyloarthritis | 3 | Completed | AbbVie | Feb 21, 2017 | 673 |
| NCT01752855Arthritis, Rheumatoid · United States, Belgium, Czech Republic and more | 2 | Completed | AbbVie | Oct 2013 | 88 |
| NCT01712178Arthritis, Rheumatoid · United States, Belgium, Czech Republic and more | 2 | Completed | AbbVie | May 2013 | 100 |
How it is read
Names in the registry
- “Adalimumab”, 69 entries
- “adalimumab”, 63 entries
- “MSB11022”, 3 entries
- “M923”, 3 entries
- “Humira (adalimumab)”, 3 entries
Codes read as this program: AVT02.
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 45 studies
- Psoriasis, 25 studies
- Crohn Disease, 23 studies
- Colitis, Ulcerative, 9 studies
- Hidradenitis Suppurativa, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.